Prostate Cancer, Science and Clinical Practice, Second Edition, continues to be an important translational reference that bridges the gap between science and clinical medicine. It reviews the biological processes that can be implicated in the disease, reviews current treatments, highlights the pitfalls where relevant, and examines the scientific developments that might result in future treatments.
Key chapters from the previous edition have been updated, and a plethora of new chapters describe new concepts of prostate cancer biology and newly developed therapeutics. Each chapter has been written by internationally recognized specialists on prostate cancer epidemiology, genetic susceptibility, cancer metastases, prostate physiology, proteomics, new therapeutics, and clinical trials.
- Presents a comprehensive, translational source for all aspects of prostate cancer in one reference work
- Provides a common language for cancer researchers, oncologists, and urologists to discuss prostate tumors and how prostate cancer metastases affects other major organ systems
- Offers insights to research clinicians, giving them a key understanding the molecular basis of prostate cancer
- Offers insights to cancer researchers into how clinical observations and practices can feed back into the research cycle and, therefore, can contribute to the development of more targeted genomic and proteomic assays
Prostate Cancer, Science and Clinical Practice, Second Edition, continues to be an important translational reference that bridges the gap between science and clinical medicine. It reviews the biological processes that can be implicated in the disease, reviews current treatments, highlights the pitfalls where relevant, and examines the scientific developments that might result in future treatments. Key chapters from the previous edition have been updated, and a plethora of new chapters describe new concepts of prostate cancer biology and newly developed therapeutics. Each chapter has been written by internationally recognized specialists on prostate cancer epidemiology, genetic susceptibility, cancer metastases, prostate physiology, proteomics, new therapeutics, and clinical trials. Presents a comprehensive, translational source for all aspects of prostate cancer in one reference work Provides a common language for cancer researchers, oncologists, and urologists to discuss prostate tumors and how prostate cancer metastases affects other major organ systems Offers insights to research clinicians, giving them a key understanding the molecular basis of prostate cancer Offers insights to cancer researchers into how clinical observations and practices can feed back into the research cycle and, therefore, can contribute to the development of more targeted genomic and proteomic assays
List of Contributors
Philip H. Abbosh MD, PhD, Department of Surgical Oncology, Fox Chase Cancer Center-Temple Health, Philadelphia, PA, USA
Firas Abdollah MD, Vattikuti Urology Institute & VUI Center for Outcomes Research Analytics and Evaluation, Henry Ford Hospital, Detroit, MI, USA
Mohan P. Achary PhD, Department of Radiation Oncology and Radiology, Temple University School of Medicine, Philadelphia, PA, USA
Shaheen Alanee MD, MPH, Division of Urology, Department of Surgery, Southern Illinois University School of Medicine, Springfield, IL, USA
Peter C. Albertsen MD, MS, Department of Surgery, University of Connecticut Health Center, Farmington, CT, USA
Yousef Al-Shraideh MD, Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
Gerald Andriole MD, Division of Urological Surgery, Washington University in St. Louis, St. Louis, MO, USA
Janet E. Baack Kukreja MD, Department of Urology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
Richard K. Babayan MD, Boston University School of Medicine, Boston, MA, USA
Brock R. Baker BS, Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC, USA
Christopher E. Bayne MD, Department of Urology, The George Washington University, Washington, DC, USA
Marijo Bilusic MD, PhD, Department of Medical Oncology, Fox Chase Cancer Center/Temple University, Philadelphia, PA, USA
Leonard P. Bokhorst MD, Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
David B. Cahn DO, MBS, Department of Urology, Einstein Healthcare Network, Philadelphia, PA, USA
Daniel J. Canter MD, Department of Urology, Fox Chase Cancer Center and Einstein Healthcare Network, Philadelphia, PA, USA
David Y.T. Chen MD, FACS, Department of Surgical Oncology, Fox Chase Cancer Center-Temple Health, Philadelphia, PA, USA
Ronald C. Chen MD, MPH, Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC, USA
Juan Chipollini MD, Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA
Peter L. Choyke MD, Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Matthew R. Cooperberg MD, MPH, Department of Urology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA
Anthony Costello MD, FRACS, FRCSI, Departments of Urology and Surgery, Royal Melbourne Hospital and University of Melbourne, Melbourne; Epworth Prostate Centre, Epworth Healthcare, Melbourne, Australia
E. David Crawford MD, University of Colorado Health Science Center, Aurora, CO, USA
Curtiland Deville MD, Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, Sibley Memorial Hospital, Washington, DC, USA
Essel Dulaimi MD, Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA
Danuta Dynda MD, Division of Urology, Department of Surgery, Southern Illinois University School of Medicine, Springfield, IL, USA
John B. Eifler MD, Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA
Cesar E. Ercole MD, Center for Urologic Oncology, Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
Daniel D. Eun MD, Department of Urology, Temple University Hospital, Philadelphia, PA, USA
Wouter Everaerts MD, PhD, Division of Cancer Surgery, Peter MacCallum Cancer Centre, University of Melbourne, East Melbourne; Department of Urology, Royal Melbourne Hospital, Parkville; and Epworth Prostate Centre, Epworth Healthcare, Richmond, Victoria, Australia
Izak Faiena MD, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Division of Urology, Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
Michael A. Ferragamo MD, FACS, Department of Urology, State University of New York, University Hospital, Stony Brook, NY, USA
Chandra K. Flack MD, Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA
Tullika Garg MD, MPH, Urology Department, Geisinger Health System, Danville, PA, USA
Awet Gherezghihir MD, Department of Surgery (Urology), The Penn State Milton S. Hershey Medical Center, Hershey, PA, USA
Ciril J. Godec MD, PhD, Department of Urology, SUNY Downstate University School of Medicine, Brooklyn, NY; Long Island College Hospital, Long Island, NY, USA
Leonard G. Gomella MD, Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
Richard E. Greenberg MD, FACS, Division of Urologic Oncology, Fox Chase Cancer Center, and Temple University School of Medicine, Philadelphia, PA, USA
Baruch Mayer Grob MD, Urology Section, Hunter Holmes McGuire VA Medical Center, and Division of Urology, Virginia Commonwealth University Health System, Richmond, VA, USA
Giorgio Guazzoni MD, Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele, Milan, Italy
Thomas J. Guzzo MD, MPH, Division of Urology, The Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Ahmed Haddad MBChB, PhD, Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
Maahum Haider MD, Department of Urology, University of Washington School of Medicine, Seattle, WA, USA
Andrew C. Harbin MD, Department of Urology, Temple University Hospital, Philadelphia, PA, USA
Eric M. Horwitz MD, Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Ahmed A. Hussein MD, Department of Urology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA; Department of Urology, Cairo University, Oula, Giza, Egypt
Timothy Ito MD, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Thomas W. Jarrett MD, Department of Urology, The George Washington University, Washington, DC, USA
Lawrence C. Jenkins MD, MBA, Sexual and Reproductive Medicine Program, Urology Service, Memorial...
Erscheint lt. Verlag | 29.9.2015 |
---|---|
Sprache | englisch |
Themenwelt | Informatik ► Weitere Themen ► Bioinformatik |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Urologie | |
Naturwissenschaften ► Biologie ► Genetik / Molekularbiologie | |
ISBN-10 | 0-12-800592-0 / 0128005920 |
ISBN-13 | 978-0-12-800592-7 / 9780128005927 |
Haben Sie eine Frage zum Produkt? |
![PDF](/img/icon_pdf_big.jpg)
Größe: 56,8 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
![EPUB](/img/icon_epub_big.jpg)
Größe: 43,9 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich